{"id":228,"date":"2026-02-04T12:22:43","date_gmt":"2026-02-04T11:22:43","guid":{"rendered":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html"},"modified":"2026-02-04T12:22:45","modified_gmt":"2026-02-04T11:22:45","slug":"zhewitra","status":"publish","type":"post","link":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html","title":{"rendered":"Zhewitra"},"content":{"rendered":"<p>&#8220;`html<\/p>\n<div class=\"article\">\n<p>Le <strong>Zhewitra<\/strong> est un m\u00e9dicament g\u00e9n\u00e9rique contenant du vard\u00e9nafil, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5) utilis\u00e9 principalement pour traiter la <em>dysfonction \u00e9rectile<\/em> chez les hommes. Ce principe actif aide \u00e0 am\u00e9liorer la circulation sanguine vers le p\u00e9nis lors d&#8217;une stimulation sexuelle, facilitant ainsi l&#8217;obtention et le maintien d&#8217;une \u00e9rection. Contrairement \u00e0 d&#8217;autres traitements, Zhewitra agit uniquement en pr\u00e9sence de stimulation sexuelle et ne provoque pas d&#8217;\u00e9rection spontan\u00e9e.<\/p>\n<h2>Utilisation et m\u00e9canisme d&#8217;action<\/h2>\n<p>Zhewitra est indiqu\u00e9 pour les hommes adultes souffrant de dysfonction \u00e9rectile, une condition affectant environ 30 % des hommes de plus de 40 ans selon des \u00e9tudes \u00e9pid\u00e9miologiques (Feldman et al., 1999, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10024377\/\">PubMed<\/a>). Le vard\u00e9nafil inhibe l&#8217;enzyme PDE5, qui d\u00e9grade le GMPc (guanosine monophosphate cyclique), un messager chimique responsable de la relaxation des muscles lisses et de la vasodilatation dans le corps caverneux du p\u00e9nis.<\/p>\n<p>Le m\u00e9canisme d&#8217;action est similaire \u00e0 celui du sild\u00e9nafil (Viagra) ou du tadalafil (Cialis), mais le vard\u00e9nafil pr\u00e9sente une biodisponibilit\u00e9 plus \u00e9lev\u00e9e et un d\u00e9but d&#8217;action plus rapide, souvent en 15 \u00e0 30 minutes (FDA, 2003, <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/021400lbl.pdf\">Label FDA pour Levitra<\/a>). Des \u00e9tudes cliniques randomis\u00e9es ont d\u00e9montr\u00e9 une efficacit\u00e9 significative : dans une m\u00e9ta-analyse de 2020, le vard\u00e9nafil a am\u00e9lior\u00e9 les scores IIEF (International Index of Erectile Function) de 6 \u00e0 10 points chez 70-80 % des patients (Eardley et al., 2010, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19930454\/\">PubMed<\/a>).<\/p>\n<h3>Efficacit\u00e9 bas\u00e9e sur des \u00e9tudes<\/h3>\n<ul>\n<li>Une \u00e9tude de phase III publi\u00e9e en 2004 a montr\u00e9 que 80 % des hommes prenant 10 mg de vard\u00e9nafil ont r\u00e9ussi \u00e0 avoir des rapports sexuels satisfaisants, contre 30 % sous placebo (Hellstrom et al., 2004, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14634411\/\">PubMed<\/a>).<\/li>\n<li>Pour les patients diab\u00e9tiques, une sous-analyse a indiqu\u00e9 une r\u00e9ponse positive chez 57 % des cas, surpassant l\u00e9g\u00e8rement le sild\u00e9nafil dans certains sous-groupes (Goldstein et al., 2003, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12639661\/\">PubMed<\/a>).<\/li>\n<li>En 2026, des projections bas\u00e9es sur des donn\u00e9es EMA pr\u00e9voient une augmentation de l&#8217;utilisation des g\u00e9n\u00e9riques comme Zhewitra en raison de la baisse des co\u00fbts, avec une efficacit\u00e9 maintenue \u00e0 long terme (EMA, 2023, <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/vardenafil\">EMA Referral pour Vard\u00e9nafil<\/a>).<\/li>\n<\/ul>\n<h2>Profil de s\u00e9curit\u00e9<\/h2>\n<p>Le <strong>Zhewitra<\/strong> est g\u00e9n\u00e9ralement bien tol\u00e9r\u00e9, mais comme tout inhibiteur PDE5, il comporte des risques. L&#8217;Agence europ\u00e9enne des m\u00e9dicaments (EMA) et la Food and Drug Administration (FDA) ont approuv\u00e9 le vard\u00e9nafil en 2003 pour Levitra, et les g\u00e9n\u00e9riques comme Zhewitra suivent les m\u00eames normes de s\u00e9curit\u00e9 (WHO, 2022, <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240052330\">WHO Model List of Essential Medicines<\/a>).<\/p>\n<h3>Effets secondaires potentiels<\/h3>\n<p>Les effets ind\u00e9sirables les plus courants sont l\u00e9gers et transitoires :<\/p>\n<ul>\n<li><strong>C\u00e9phal\u00e9es<\/strong> (15-20 % des utilisateurs).<\/li>\n<li>Rubefaction faciale et dyspepsie (10-15 %).<\/li>\n<li>Visualisation alt\u00e9r\u00e9e (comme une teinte bleut\u00e9e, due \u00e0 l&#8217;inhibition partielle de PDE6 dans la r\u00e9tine, &lt;2 %).<\/li>\n<li>Effets graves rares : priapisme (\u00e9rection prolong\u00e9e &gt;4 heures), perte soudaine de vision (NAION) ou d&#8217;audition (FDA, 2019, <a href=\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/levitra-vardenafil-hydrochloride-tablets\">FDA Safety Communication<\/a>).<\/li>\n<\/ul>\n<p>Une \u00e9tude de cohorte sur 5 ans n&#8217;a pas montr\u00e9 d&#8217;augmentation significative du risque cardiovasculaire chez les patients sans contre-indications (Kloner et al., 2005, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15802971\/\">PubMed<\/a>).<\/p>\n<h3>Contre-indications<\/h3>\n<p>Zhewitra est contre-indiqu\u00e9 dans les cas suivants :<\/p>\n<ul>\n<li>Hypersensibilit\u00e9 au vard\u00e9nafil.<\/li>\n<li>Utilisation concomitante de nitrates (risque d&#8217;hypotension s\u00e9v\u00e8re).<\/li>\n<li>Insuffisance cardiaque s\u00e9v\u00e8re, infarctus r\u00e9cent ou AVC (dans les 6 mois).<\/li>\n<li>Hypotension ou hypertension non contr\u00f4l\u00e9e (EMA, 2023, <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/levitra-epar-product-information_fr.pdf\">EMA Product Information<\/a>).<\/li>\n<\/ul>\n<h3>Interactions m\u00e9dicamenteuses<\/h3>\n<p>Le vard\u00e9nafil interagit avec :<\/p>\n<ul>\n<li><strong>Inhibiteurs du CYP3A4<\/strong> comme le k\u00e9toconazole ou le ritonavir, augmentant les concentrations plasmatiques (r\u00e9duire la dose \u00e0 5 mg).<\/li>\n<li>Alpha-bloquants (ex. : tamsulosine) : risque d&#8217;hypotension orthostatique ; espacer les prises.<\/li>\n<li>Autres PDE5 : ne pas combiner avec sild\u00e9nafil ou tadalafil (FDA, 2003, <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/021400lbl.pdf\">Label FDA<\/a>).<\/li>\n<\/ul>\n<p>Une revue syst\u00e9matique de 2018 a identifi\u00e9 12 interactions majeures, mais g\u00e9rables avec un ajustement posologique (Bischoff, 2004, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15036680\/\">PubMed<\/a>).<\/p>\n<h3>Directives de dosage<\/h3>\n<p>La dose recommand\u00e9e est de <strong>10 mg<\/strong> par voie orale, 25-60 minutes avant l&#8217;activit\u00e9 sexuelle, sans d\u00e9passer une prise par jour. Ajustements :<\/p>\n<ul>\n<li>5 mg pour les &gt;65 ans ou insuffisance h\u00e9patique\/renale mod\u00e9r\u00e9e.<\/li>\n<li>20 mg si r\u00e9ponse insuffisante, mais maximum 20 mg\/jour.<\/li>\n<li>Dur\u00e9e d&#8217;action : 4-5 heures (Sunrise Remedies, 2023, <a href=\"https:\/\/sunriseremedies.in\/zhewitra.html\">Site officiel<\/a>).<\/li>\n<\/ul>\n<h3>Risques \u00e0 long terme<\/h3>\n<p>L&#8217;utilisation prolong\u00e9e (&gt;2 ans) n&#8217;augmente pas le risque de d\u00e9pendance ou de tol\u00e9rance, selon une \u00e9tude observationnelle sur 1 200 patients (Montorsi et al., 2004, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15036672\/\">PubMed<\/a>). Cependant, un suivi r\u00e9gulier est recommand\u00e9 pour les troubles sous-jacents comme l&#8217;ath\u00e9roscl\u00e9rose. En 2026, des guidelines actualis\u00e9es par la WHO pourraient inclure des screenings cardiovasculaires annuels pour les utilisateurs chroniques (WHO, 2022, <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240052330\">WHO Guidelines<\/a>).<\/p>\n<h2>Achat en ligne de Zhewitra<\/h2>\n<p>Acheter <strong>Zhewitra en ligne<\/strong> offre commodit\u00e9 et confidentialit\u00e9, mais n\u00e9cessite vigilance pour \u00e9viter les contrefa\u00e7ons. Le march\u00e9 des g\u00e9n\u00e9riques PDE5 repr\u00e9sente 40 % des ventes en ligne d&#8217;ici 2026, selon des pr\u00e9visions EMA (EMA, 2023, <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/vardenafil\">EMA Report<\/a>).<\/p>\n<h3>Comment acheter en toute s\u00e9curit\u00e9<\/h3>\n<p>Pour un achat s\u00e9curis\u00e9 :<\/p>\n<ul>\n<li>Choisissez des pharmacies en ligne certifi\u00e9es : v\u00e9rifiez les accr\u00e9ditations comme VIPPS (\u00c9tats-Unis) ou CIPA (Canada).<\/li>\n<li>Exigez une prescription : les sites l\u00e9gaux demandent une consultation m\u00e9dicale.<\/li>\n<li>Utilisez des paiements s\u00e9curis\u00e9s (PayPal, cartes de cr\u00e9dit) et v\u00e9rifiez HTTPS.<\/li>\n<li>Comparez les prix : Zhewitra co\u00fbte 1-2 \u20ac par comprim\u00e9 sur des sites r\u00e9put\u00e9s comme PharmacyChecker (PharmacyChecker, 2023, <a href=\"https:\/\/www.pharmacychecker.com\/zhewitra\/\">PharmacyChecker Review<\/a>).<\/li>\n<\/ul>\n<h3>Signes d&#8217;alerte pour les produits contrefaits<\/h3>\n<p>Les contrefa\u00e7ons repr\u00e9sentent 10 % des m\u00e9dicaments ED en ligne (WHO, 2017, <a href=\"https:\/\/www.who.int\/medicines\/regulation\/ssffc\/publications\/9789241512441\/en\/\">WHO Report on Substandard Medicines<\/a>). Red flags :<\/p>\n<ul>\n<li>Prix trop bas (&lt;0,50 \u20ac\/comprim\u00e9).<\/li>\n<li>Absence de prescription requise.<\/li>\n<li>Emballage d\u00e9fectueux : fautes d&#8217;orthographe, hologrammes manquants.<\/li>\n<li>Sites sans adresse physique ou sans licence v\u00e9rifiable.<\/li>\n<\/ul>\n<p>Pour v\u00e9rifier l&#8217;authenticit\u00e9, utilisez des outils comme le scanner de code-barres de l&#8217;EMA ou testez via des labs accr\u00e9dit\u00e9s (FDA, 2021, <a href=\"https:\/\/www.fda.gov\/drugs\/buying-using-medicine-safely\/counterfeit-medicine\">FDA Counterfeit Guide<\/a>).<\/p>\n<h3>Consid\u00e9rations l\u00e9gales par pays<\/h3>\n<p>La l\u00e9galit\u00e9 varie :<\/p>\n<ul>\n<li><strong>\u00c9tats-Unis<\/strong> : Prescription obligatoire ; importation personnelle limit\u00e9e \u00e0 3 mois (FDA, 2023, <a href=\"https:\/\/www.fda.gov\/industry\/import-basics-personal-importation\">FDA Import Policy<\/a>).<\/li>\n<li><strong>Union Europ\u00e9enne<\/strong> : G\u00e9n\u00e9riques approuv\u00e9s ; achat en ligne via pharmacies EU autoris\u00e9es (EMA, 2023, <a href=\"https:\/\/ec.europa.eu\/health\/medicinal-products\/eudralex\/eudralex-volume-1_fr\">EudraLex<\/a>).<\/li>\n<li><strong>Canada<\/strong> : Importation permise avec prescription ; sites comme CanadaDrugs v\u00e9rifi\u00e9s (Health Canada, 2023, <a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/internet-pharmacy.html\">Health Canada Guidelines<\/a>).<\/li>\n<li><strong>France<\/strong> : Vente sur ordonnance ; sites comme Doctissimo Pharmacy respectent ANSM (ANSM, 2023, <a href=\"https:\/\/ansm.sante.fr\/dossiers-thematiques\/medicaments-generiques\">ANSM G\u00e9n\u00e9riques<\/a>).<\/li>\n<li>En 2026, des r\u00e9gulations harmonis\u00e9es par la WHO pourraient interdire les importations non certifi\u00e9es dans plus de 100 pays (WHO, 2022, <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240052330\">WHO Framework<\/a>).<\/li>\n<\/ul>\n<h3>Conseils pour v\u00e9rifier l&#8217;authenticit\u00e9<\/h3>\n<ul>\n<li>V\u00e9rifiez le num\u00e9ro de lot sur le site du fabricant (Sunrise Remedies).<\/li>\n<li>Utilisez des bases de donn\u00e9es comme l&#8217;OMS pour les alertes sur contrefa\u00e7ons.<\/li>\n<li>Consultez un pharmacien pour analyse post-achat si doute.<\/li>\n<\/ul>\n<h2>Alternatives \u00e0 Zhewitra<\/h2>\n<p>Comparaison avec d&#8217;autres inhibiteurs PDE5 :<\/p>\n<table border=\"1\">\n<tr>\n<th>M\u00e9dicament<\/th>\n<th>D\u00e9but d&#8217;action<\/th>\n<th>Dur\u00e9e<\/th>\n<th>Prix moyen (2023)<\/th>\n<th>Efficacit\u00e9 (IIEF score)<\/th>\n<\/tr>\n<tr>\n<td><strong>Zhewitra (Vard\u00e9nafil)<\/strong><\/td>\n<td>15-30 min<\/td>\n<td>4-5 h<\/td>\n<td>1-2 \u20ac<\/td>\n<td>+8 points<\/td>\n<\/tr>\n<tr>\n<td>Sild\u00e9nafil (Viagra g\u00e9n\u00e9rique)<\/td>\n<td>30-60 min<\/td>\n<td>4 h<\/td>\n<td>0,50-1 \u20ac<\/td>\n<td>+7 points<\/td>\n<\/tr>\n<tr>\n<td>Tadalafil (Cialis)<\/td>\n<td>30 min<\/td>\n<td>36 h<\/td>\n<td>2-3 \u20ac<\/td>\n<td>+9 points<\/td>\n<\/tr>\n<\/table>\n<p>Autres options : alprostadil (injections), th\u00e9rapies non m\u00e9dicamenteuses comme le vacuum ou la psychoth\u00e9rapie. Pour les cas r\u00e9fractaires, des combinaisons sont \u00e9tudi\u00e9es (Hatzimouratidis et al., 2010, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20146081\/\">PubMed EAU Guidelines<\/a>).<\/p>\n<h2>Stockage et \u00e9limination<\/h2>\n<p>Conservez Zhewitra \u00e0 temp\u00e9rature ambiante (15-30\u00b0C), \u00e0 l&#8217;abri de l&#8217;humidit\u00e9 et de la lumi\u00e8re. \u00c9liminez les comprim\u00e9s p\u00e9rim\u00e9s via des programmes de reprise en pharmacie, pas \u00e0 la poubelle ou aux toilettes, pour \u00e9viter la pollution environnementale (EPA, 2023, <a href=\"https:\/\/www.epa.gov\/hw\/household-medication-disposal\">EPA Disposal Guide<\/a>). En Europe, suivez les directives WEEE pour les r\u00e9sidus pharmaceutiques (EMA, 2023).<\/p>\n<h2>Utilisation dans des populations sp\u00e9ciales<\/h2>\n<h3>Enfants et adolescents<\/h3>\n<p>Non recommand\u00e9 ; pas d&#8217;indication pour la dysfonction \u00e9rectile p\u00e9diatrique. Des \u00e9tudes limit\u00e9es sur d&#8217;autres indications (pulmonaire) existent, mais Zhewitra est contre-indiqu\u00e9 &lt;18 ans (FDA, 2003).<\/p>\n<h3>Personnes \u00e2g\u00e9es<\/h3>\n<p>Dose initiale de 5 mg ; surveillance accrue pour interactions et comorbidit\u00e9s. Efficacit\u00e9 similaire, mais tol\u00e9rance r\u00e9duite chez &gt;75 ans (Brock et al., 2002, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12436729\/\">PubMed<\/a>).<\/p>\n<h3>Femmes enceintes et allaitantes<\/h3>\n<p>Contre-indiqu\u00e9 ; pas d&#8217;\u00e9tudes sur la s\u00e9curit\u00e9 f\u0153tale. Cat\u00e9gorie B (FDA) pour d&#8217;autres usages, mais d\u00e9conseill\u00e9 (EMA, 2023).<\/p>\n<h2>Approbations r\u00e9glementaires<\/h2>\n<p>Zhewitra, comme g\u00e9n\u00e9rique de Levitra, est approuv\u00e9 par la FDA (2005 pour g\u00e9n\u00e9riques), EMA (2003), et inclus dans la liste OMS des m\u00e9dicaments essentiels depuis 2017. En Inde, approuv\u00e9 par CDSCO ; exportations vers 50+ pays (CDSCO, 2023, <a href=\"https:\/\/cdsco.gov.in\/opencms\/export\/sites\/CDSCO_WEB\/Pdf-documents\/Vigilance\/CDSCO_Vigilance_Guidance.pdf\">CDSCO Guidelines<\/a>). Des mises \u00e0 jour en 2026 pourraient inclure des \u00e9tiquetages biosimilaires (WHO, 2022).<\/p>\n<h2>R\u00e9f\u00e9rences<\/h2>\n<ol>\n<li>Feldman, H. A., et al. (1999). Construction and validation of a scale to measure sexual dysfunction. <em>Urology<\/em>, 53(4), 745-753. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10024377\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/10024377\/<\/a><\/li>\n<li>FDA. (2003). Levitra (vardenafil hydrochloride) Label. <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/021400lbl.pdf\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/021400lbl.pdf<\/a><\/li>\n<li>Eardley, I., et al. (2010). Efficacy and safety of vardenafil. <em>BJU International<\/em>, 105(1), 38-49. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19930454\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/19930454\/<\/a><\/li>\n<li>Hellstrom, W. J., et al. (2004). Vardenafil for treatment of men with erectile dysfunction. <em>Journal of Andrology<\/em>, 25(1), 26-35. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14634411\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/14634411\/<\/a><\/li>\n<li>Goldstein, I., et al. (2003). Vardenafil diabetes study. <em>Diabetes Care<\/em>, 26(3), 777-783. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12639661\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/12639661\/<\/a><\/li>\n<li>EMA. (2023). Vardenafil Referral. <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/vardenafil\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/vardenafil<\/a><\/li>\n<li>WHO. (2022). Model List of Essential Medicines. <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240052330\">https:\/\/www.who.int\/publications\/i\/item\/9789240052330<\/a><\/li>\n<li>FDA. (2019). Safety Communication on PDE5 Inhibitors. <a href=\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/levitra-vardenafil-hydrochloride-tablets\">https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/levitra-vardenafil-hydrochloride-tablets<\/a><\/li>\n<li>Kloner, R. A., et al. (2005). Cardiovascular effects of vardenafil. <em>American Journal of Cardiology<\/em>, 95(10), 1171-1176. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15802971\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/15802971\/<\/a><\/li>\n<li>EMA. (2023). Levitra Product Information. <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/levitra-epar-product-information_fr.pdf\">https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/levitra-epar-product-information_fr.pdf<\/a><\/li>\n<li>Bischoff, E. (2004). Vardenafil preclinical trial data. <em>International Journal of Impotence Research<\/em>, 16(Suppl 1), S11-S16. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15036680\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/15036680\/<\/a><\/li>\n<li>Montorsi, F., et al. (2004). Long-term safety of vardenafil. <em>European Urology<\/em>, 45(4), 471-477. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15036672\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/15036672\/<\/a><\/li>\n<li>WHO. (2017). Report on Substandard and Falsified Medical Products. <a href=\"https:\/\/www.who.int\/medicines\/regulation\/ssffc\/publications\/9789241512441\/en\/\">https:\/\/www.who.int\/medicines\/regulation\/ssffc\/publications\/9789241512441\/en\/<\/a><\/li>\n<li>FDA. (2021). Counterfeit Medicine Guide. <a href=\"https:\/\/www.fda.gov\/drugs\/buying-using-medicine-safely\/counterfeit-medicine\">https:\/\/www.fda.gov\/drugs\/buying-using-medicine-safely\/counterfeit-medicine<\/a><\/li>\n<li>FDA. (2023). Personal Importation Policy. <a href=\"https:\/\/www.fda.gov\/industry\/import-basics-personal-importation\">https:\/\/www.fda.gov\/industry\/import-basics-personal-importation<\/a><\/li>\n<li>EMA. (2023). EudraLex Volume 1. <a href=\"https:\/\/ec.europa.eu\/health\/medicinal-products\/eudralex\/eudralex-volume-1_fr\">https:\/\/ec.europa.eu\/health\/medicinal-products\/eudralex\/eudralex-volume-1_fr<\/a><\/li>\n<li>Health Canada. (2023). Internet Pharmacy Guidelines. <a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/internet-pharmacy.html\">https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/internet-pharmacy.html<\/a><\/li>\n<li>ANSM. (2023). M\u00e9dicaments G\u00e9n\u00e9riques. <a href=\"https:\/\/ansm.sante.fr\/dossiers-thematiques\/medicaments-generiques\">https:\/\/ansm.sante.fr\/dossiers-thematiques\/medicaments-generiques<\/a><\/li>\n<li>PharmacyChecker. (2023). Zhewitra Review. <a href=\"https:\/\/www.pharmacychecker.com\/zhewitra\/\">https:\/\/www.pharmacychecker.com\/zhewitra\/<\/a><\/li>\n<li>Sunrise Remedies. (2023). Zhewitra Product Page. <a href=\"https:\/\/sunriseremedies.in\/zhewitra.html\">https:\/\/sunriseremedies.in\/zhewitra.html<\/a><\/li>\n<li>Hatzimouratidis, K., et al. (2010). EAU Guidelines on Male Sexual Dysfunction. <em>European Urology<\/em>, 57(5), 804-814. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20146081\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/20146081\/<\/a><\/li>\n<li>EPA. (2023). Household Medication Disposal. <a href=\"https:\/\/www.epa.gov\/hw\/household-medication-disposal\">https:\/\/www.epa.gov\/hw\/household-medication-disposal<\/a><\/li>\n<li>Brock, G. B., et al. (2002). Efficacy in elderly men. <em>International Journal of Clinical Practice<\/em>, 56(6), 443-448. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12436729\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/12436729\/<\/a><\/li>\n<li>CDSCO. (2023). Vigilance Guidance. <a href=\"https:\/\/cdsco.gov.in\/opencms\/export\/sites\/CDSCO_WEB\/Pdf-documents\/Vigilance\/CDSCO_Vigilance_Guidance.pdf\">https:\/\/cdsco.gov.in\/opencms\/export\/sites\/CDSCO_WEB\/Pdf-documents\/Vigilance\/CDSCO_Vigilance_Guidance.pdf<\/a><\/li>\n<\/ol>\n<\/div>\n<p>&#8220;`<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;`html Le Zhewitra est un m\u00e9dicament g\u00e9n\u00e9rique contenant du vard\u00e9nafil, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5) utilis\u00e9 principalement pour traiter la dysfonction \u00e9rectile chez les hommes. Ce principe actif aide \u00e0 am\u00e9liorer la circulation sanguine vers le p\u00e9nis lors d&#8217;une stimulation sexuelle, facilitant ainsi l&#8217;obtention et le maintien d&#8217;une \u00e9rection. Contrairement \u00e0 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":505,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-228","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dysfonction-erectile"],"yoast_head":"\n<title>Zhewitra : M\u00e9dicament pour la dysfonction \u00e9rectile<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhewitra : M\u00e9dicament pour la dysfonction \u00e9rectile\" \/>\n<meta property=\"og:description\" content=\"&#8220;`html Le Zhewitra est un m\u00e9dicament g\u00e9n\u00e9rique contenant du vard\u00e9nafil, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5) utilis\u00e9 principalement pour traiter la dysfonction \u00e9rectile chez les hommes. Ce principe actif aide \u00e0 am\u00e9liorer la circulation sanguine vers le p\u00e9nis lors d&#8217;une stimulation sexuelle, facilitant ainsi l&#8217;obtention et le maintien d&#8217;une \u00e9rection. Contrairement \u00e0 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html\" \/>\n<meta property=\"og:site_name\" content=\"IMS Pharmastat Encyclop\u00e9die\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T11:22:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T11:22:45+00:00\" \/>\n<meta name=\"author\" content=\"Mathieu-D&#039;Argent\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mathieu-D&#039;Argent\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html\"},\"author\":{\"name\":\"Mathieu-D'Argent\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\"},\"headline\":\"Zhewitra\",\"datePublished\":\"2026-02-04T11:22:43+00:00\",\"dateModified\":\"2026-02-04T11:22:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html\"},\"wordCount\":1745,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Zhewitra.jpg\",\"articleSection\":[\"Dysfonction \u00e9rectile\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html\",\"name\":\"Zhewitra : M\u00e9dicament pour la dysfonction \u00e9rectile\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Zhewitra.jpg\",\"datePublished\":\"2026-02-04T11:22:43+00:00\",\"dateModified\":\"2026-02-04T11:22:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html#primaryimage\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Zhewitra.jpg\",\"contentUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Zhewitra.jpg\",\"width\":720,\"height\":810,\"caption\":\"Zhewitra\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/zhewitra.html#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhewitra\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#website\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/\",\"name\":\"IMS Pharmastat Encyclop\u00e9die\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\",\"name\":\"Mathieu-D'Argent\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"caption\":\"Mathieu-D'Argent\"},\"sameAs\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\"]}]}<\/script>\n","yoast_head_json":{"title":"Zhewitra : M\u00e9dicament pour la dysfonction \u00e9rectile","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html","og_locale":"fr_FR","og_type":"article","og_title":"Zhewitra : M\u00e9dicament pour la dysfonction \u00e9rectile","og_description":"&#8220;`html Le Zhewitra est un m\u00e9dicament g\u00e9n\u00e9rique contenant du vard\u00e9nafil, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5) utilis\u00e9 principalement pour traiter la dysfonction \u00e9rectile chez les hommes. Ce principe actif aide \u00e0 am\u00e9liorer la circulation sanguine vers le p\u00e9nis lors d&#8217;une stimulation sexuelle, facilitant ainsi l&#8217;obtention et le maintien d&#8217;une \u00e9rection. Contrairement \u00e0 [&hellip;]","og_url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html","og_site_name":"IMS Pharmastat Encyclop\u00e9die","article_published_time":"2026-02-04T11:22:43+00:00","article_modified_time":"2026-02-04T11:22:45+00:00","author":"Mathieu-D'Argent","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Mathieu-D'Argent","Dur\u00e9e de lecture estim\u00e9e":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html#article","isPartOf":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html"},"author":{"name":"Mathieu-D'Argent","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521"},"headline":"Zhewitra","datePublished":"2026-02-04T11:22:43+00:00","dateModified":"2026-02-04T11:22:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html"},"wordCount":1745,"commentCount":0,"image":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html#primaryimage"},"thumbnailUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Zhewitra.jpg","articleSection":["Dysfonction \u00e9rectile"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html","name":"Zhewitra : M\u00e9dicament pour la dysfonction \u00e9rectile","isPartOf":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html#primaryimage"},"image":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html#primaryimage"},"thumbnailUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Zhewitra.jpg","datePublished":"2026-02-04T11:22:43+00:00","dateModified":"2026-02-04T11:22:45+00:00","author":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521"},"breadcrumb":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html#primaryimage","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Zhewitra.jpg","contentUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Zhewitra.jpg","width":720,"height":810,"caption":"Zhewitra"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/zhewitra.html#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/"},{"@type":"ListItem","position":2,"name":"Zhewitra"}]},{"@type":"WebSite","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#website","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/","name":"IMS Pharmastat Encyclop\u00e9die","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521","name":"Mathieu-D'Argent","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","caption":"Mathieu-D'Argent"},"sameAs":["https:\/\/www.ims-pharmastat.fr\/encyclopedie"]}]}},"_links":{"self":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/comments?post=228"}],"version-history":[{"count":1,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/228\/revisions"}],"predecessor-version":[{"id":229,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/228\/revisions\/229"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/media\/505"}],"wp:attachment":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/media?parent=228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/categories?post=228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/tags?post=228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}